Published: 2020-09-23 15:59 | Updated: 2020-09-23 16:02

Current calls, week 39, 2020

Tips from KI Grants Office about current calls.

Swedish and Nordic calls

Wera Ekströms fond för pediatrikforskning

Wera Ekströms Stiftelse för pediatrisk forskning inbjuder ansökningar om forskningsanslag. Dessa stöder pediatrisk forskning, i första hand med inriktning på de sjukdomstillstånd som drabbar ämnesomsättningen. Följande typer av anslag finns tillgängliga:

•forskarrekryteringsstipendier värda SEK 15,000 per månad, att använda före registrering till forskarutbildningen som doktorand;

•stipendier för registrerade forskarstuderande värda SEK 17,000 per månad;

•stipendier för disputerade forskare värda SEK 22,000 per månad.

Stipendierna är avsedda för heltidsstudier och yngre forskare prioriteras.

Den totala budgeten uppgår till SEK 500,000.

Closing date: 1 October 2020

Further information

Anslag för aidsforskning - Stiftelsen Läkare Mot AIDS Forskningsfond

Stöder svensk forskning kring prevention, behandling och vård av hivinfektion och aids. Maximalt beviljat belopp per ansökan är SEK 200,000.

Closing date: 1 October 2020

Further information

Ottarfonden Riksförbundet för Sexuell Upplysning

Stöder vetenskaplig forskning, undervisning och upplysning som i Sverige eller internationellt främjar familjeplanering. 

Closing date: 15 October 2020

Further information

Forskningsstipendium inom gynekologisk onkologi - Svensk Onkologisk Förening

Stöder klinisk forskning inom gynekologiska tumörsjukdomar. Stipendiet är värt SEK 100,000.

Closing date: 31 October 2020

Further information

Stipendium för utveckling av kolorektal verksamhet - Svensk Förening för Kolorektal Kirurgi

Syftar till att främja utvecklingen av kolorektalkirurgin i Sverige. Två stipendium finns tillgängliga, ett värt SEK 20,000 och ett värt SEK 10,000.

Closing date: 31 October 2020

Further information

European calls

Call - Building a low-carbon, climate resilient future: Research and innovation in support of the European Green Deal

This call for proposals is a direct contribution to the European Commission’s European Green Deal Communication, which sets out the path for a fundamental transformation of Europe’s economies and societies. The call responds to the pressing need to confront the climate crisis and provide greater protection for the continent’s unique environment and biodiversity. At the same time, the call addresses the equally urgent challenge of aiding Europe’s recovery in the wake of the Covid-19 crisis, contributing directly to the EU’s Recovery Plan for Europe.

Areas with particular health perspective:

  • Call area 6: Farm to Fork
  • Call area 7: Restoring biodiversity (relevant for infectious diseases and spread of infections)
  • Call area 8: a zero-pollution ambition for a toxic-free environment (example of topics concern zero pollution solutions to protect health and exposure of industrial chemicals and pharmaceuticals.

Closing date: 26 January 2021

Further information

COVID-19 research grant - European Society of Human Reproduction and Embryology

The European Society of Human Reproduction and Embryology invites applications for its COVID-19 research grant. This supports research on the impact of SARS-CoV-2/COVID-10 on assisted reproductive technology. Two types of grants are available:

•impact of COVID-19 on patients or assisted reproductive technology, with up to €75,000;

•impact of SARS-CoV-2 on reproductive tissues, reproductive cells or assisted reproductive technology, worth up to €200,000.

Scientists and clinicians of any nationality who are members of the society.

Closing date: 15 October 2020

Further information

EFSD/Lilly exploring and applying new strategies in diabetes expand programme

European Association for the Study of Diabetes invites applications for its EFDS/Lilly exploring and applying new strategies in diabetes expand programme. This supports diabetes research projects and potential strategies that can be implemented in Europe and rolled out in low- and middle income countries to favour the improvement of quality of care for people living with diabetes. Application within any area of clinical diabetes research may be submitted with emphasis on:

•prevention of diabetes, including lifestyle and educational interventions;

•diagnosis and management of all forms of diabetes mellitus;

•diagnosis and prevention of diabetes-related microvascular and macrovascular complications.

Single non-profit institutions or groups of such institutions from Europe and associated countries may apply. Applications in collaboration with development assistance committee member countries will also be considered. Grants are generally worth €150,000 but larger grants can be awarded depending on funding requirements.

Closing date: 2 November 2020

Further information

Equipment grants - Society for Endocrinology

The Society for Endocrinology invites applications for its equipment grants. These enable members wishing to establish a laboratory and acquire pieces of equipment, part pieces of larger equipment or basic lab items. Equipment service or maintenance costs may also be covered.

Full members must have had a minimum of one year's membership and early-career members a minimum of six months membership at the time of the grant deadline. Applicants must hold a personal fellowship or be a newly appointed lecturer, or equivalent, holding a staff contract at a university or research institute, and be establishing their research group. Two grants, worth up to £10,000 each, are available.

Closing date: 11 November 2020

Further information

US calls

Federal Funding agencies

Notice of Special Interest (NOSI): The Influence of Host Resilience on Heterogeneity of Acute Respiratory Distress Syndrome/Acute Lung Injury (ARDS/ALI), NIH

Purpose: The purpose of this Notice of Special Interest (NOSI) is to inform potential applicants of the special interest of NHLBI in research to understand host resilience as a critical determinant of outcomes in acute respiratory distress syndrome (ARDS) /acute lung injury (ALI).

First available due date: October 5, 2020.

Expiration date: July 6, 2024.

Related Funding Opportunity Announcement (FOA): PA-20-183 (R01), PA-20-185 (R01).

Further information 

HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional), NIH

The purpose of this funding opportunity announcement (FOA) is to support preclinical optimization and development of safe, effective, and non-addictive small molecule and biologic therapeutics to treat pain. The goal of the program is to accelerate the optimization and development of promising small molecule and biologic hits/leads to Phase I clinical trials and readiness for the Early Phase Pain Investigation Clinical Network (EPPIC-Net) https://heal.nih.gov/research/clinical-research/eppic-net or other Phase II clinical studies. Applicants must have a promising biologic or small molecule hit/lead, robust biological rationale for the intended approach, and identified assays for optimization of the agent. The scope of this program includes optimization and early development activities, IND-enabling studies, development of a pharmacodynamic/target engagement biomarker, assembly and filing of an Investigational New Drug (IND) application and Phase I clinical testing. This is a milestone-driven phased cooperative agreement program involving participation of NIH program staff in the development of the project plan and monitoring of research progress.

Closing date: November 18, 2020, March 24, 2021, July 14, 2021, October 15, 2021, February 15, 2022, June 15, 2022, by 5:00PM local time of applicant organization.

Funding Opportunity Announcement (FOA): RFA-NS-21-010

Further information

Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R01, R21 Clinical Trial Optional), NIH

The goal of this Funding Opportunity Announcement (FOA) is to encourage applications for studies that will enhance knowledge of mechanisms associated with neuropsychiatric symptoms (NPS) in persons with Alzheimer's disease (AD) or Alzheimer's disease-related dementias (ADRD). The findings are expected to advance mechanistic understanding of both biobehavioral and neurobiological pathways leading to NPS. Findings may also provide insight into novel therapeutic targets that can be advanced into interventions to treat and prevent the development of NPS in AD and/or ADRD.

High risk/high payoff projects that lack preliminary data or utilize existing data may be most appropriate for the R21 mechanism.

Closing date: Standard dates apply. By 5:00PM local time of applicant organization until May 08, 2023.

Funding Opportunity Announcement (FOA): PAR-20-157 (R01); PAR-20-159 (R21).

Further information (R01)

Further information (R21) 

Translational Bioinformatics Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimer’s Disease (R01 Clinical Trial Optional), NIH

This Funding Opportunity Announcement (FOA) enables data-driven drug repositioning and combination therapy for Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD) by developing computational methods and data resources and/or integrating computational approaches with proof-of-concept efficacy studies in cell-based models, animal models, and/or humans.

Closing date: Standard dates apply. By 5:00PM local time of applicant organization until May 08, 2023.

Funding Opportunity Announcement (FOA): PAR-20-156.

Further information 

Alcohol and Other Drug Interactions: Unintentional Injuries and Overdoses: Epidemiology and Prevention (R01 - Clinical Trial Optional), NIH

The purpose of this funding announcement (FOA) issued by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) of the National Institutes of Health (NIH) is to encourage research grant applications that explore whether and how alcohol and other illicit drugs or illicitly used prescription drugs interact to contribute to unintentional injuries and poisonings and how to prevent and/or reduce simultaneous use of alcohol or drugs singly or in combination.

Deadline: Standard dates apply. By 5:00PM local time of applicant organization.

Funding Opportunity Announcement (FOA): PA-18-863 (R01); PA-18-861 (R03); PA-18-862 (R21).
Further information (R01)

Further information (R03)

Further information (R21)

Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed), NIH

Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) along with the National Human Genome Research Institute (NHGRI) and National Institute of Dental and Craniofacial Research (NIDCR) encourages submission of applications proposing to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate the genetic architecture of cancer risk and related outcomes (e.g., risk prediction or reduction, survival, or response to treatment, etc.). The goal of this initiative is to address key scientific questions relevant to cancer genomic and epidemiology by supporting the analysis of existing genetic or genomic datasets, in combination with other omics and environmental, clinical, behavioral, lifestyle, and molecular profiles data. Applicants are encouraged to leverage existing genetic data and perform innovative analyses of the existing data. Applications may include new research aims that are being addressed with existing data, new or advanced methods of analyses, or novel combinations and integration of datasets that allow the exploration of important scientific questions in genomic and epidemiology cancer research.

Closing date: Standard dates apply. By 5:00PM local time of applicant organization.

Funding Opportunity Announcement (FOA): PA-29-276 (R01); PA-20-277 (R21).

Further information (R01)

Further information (R21)

Leveraging Cognitive Neuroscience to Improve Assessment of Cancer Treatment-Related Cognitive Impairment (R01 Clinical Trial Optional), NIH

This FOA encourages the integration of cognitive neuroscience approaches to improve traditional assessment of acute and chronic cognitive changes following cancer treatment for non-central nervous system malignancies.

Closing date: October 14, 2020; June 9, 2021; October 13, 2021; June 8, 2022. All applications are due by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement (FOA): PA-19-340 (R01); PAR-19-339 (R21).

Further information (R01)

Further information (R21)

 

Foundation

Felloswhips & Grants, Cancer Research Institute (CRI), US

Since its inception, the Cancer Research Institute has invested hundreds of millions of dollars to support research conducted by more than 3,200 scientists and clinicians worldwide to understand the immune system and how it can be harnessed to conquer all cancers. This work has laid the foundation for nearly every major cancer immunotherapy breakthrough over the past half century.

CRI's programs provide strategic support along the entire pathway of discovery, drug development, and patient support.

  • CRI Irvington Postdoctoral Fellowship Program
    Basic laboratory research and early training for young scientists
  • Clinic and Laboratory Integration Program
    Translational research grants to top investigators
  • Lloyd J. Old STAR Award
    Flexible long-term funding for mid-career scientists
  • Technology Impact Award
    Seed funding to address the gap between technology and clinical applications
  • Impact Grants
    Funding to advance solutions to scientific and technological challenges
     

Closing date: Lloyd J. Old STAR Program January 15 (Full Application); Postdoctoral FellowshiEvery April 1 & October 1 (Full proposal); CLIP Program November 1 (LOI) ; Tech Impact Award November 15 (LOI).

Further information 

Emerging Research Grants (ERG), Hearing Health Foundation (HHF), US

For the 2021 ERG project cycle, HHF will welcome proposals in Central Auditory Processing Disorder, Children's Hearing Health, General Hearing Health, Hyperacusis, Ménière’s Disease, Tinnitus, and Usher Syndrome. HHF will award $50,000 per year for each project for an initial period of one year, renewable for one additional year.

Closing date:  The next call for applications will open on November 1, 2020.

Further information